600807.Ss
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 13.62, indicating a significant reliance on debt financing. Despite a current ratio of 1.36, suggesting moderate short-term liquidity, the company's free cash flow is negative at -879.6 million CNY, and its operating cash flow is only 14.1 million CNY, signaling potential liquidity constraints. The price-to-book ratio of 32.59 suggests that the market is valuing the company's equity at a premium relative to its book value, which may reflect expectations of future performance or intangible assets.
Profitability metrics are severely negative, with a return on equity of -10.24% and a return on assets of -0.31%, both well below industry norms. The company reported a net loss of 805.8 million CNY and an operating loss of 175.9 million CNY, indicating a significant decline in operational efficiency and profitability. Gross profit of 49.04 million CNY on total revenue of 372.18 million CNY suggests a gross margin of approximately 13.17%, which is likely below the industry median for medical equipment and supplies firms.
The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risks. However, the lack of diversification in the provided data implies that the company's performance is closely tied to a single market or product offering.
The company's growth trajectory is currently negative, with a net loss and declining operating income. The outlook for the current fiscal year is not explicitly provided, but the negative operating and net income suggest a challenging operating environment. The company's capital expenditures of -8.16 million CNY indicate a reduction in investment in long-term assets, which may signal a defensive strategy or financial constraints.
The company faces significant financial risk, with a high debt-to-equity ratio and negative net cash position. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative free cash flow and operating cash flow suggest potential challenges in meeting short-term obligations. The company has not disclosed any recent events such as filings or transcripts that would provide additional insight into its current financial or operational status.
- The company is highly leveraged with a debt-to-equity ratio of 13.62, indicating a significant reliance on debt financing.
- Profitability is severely negative, with a return on equity of -10.24% and a return on assets of -0.31%.
- The company reported a net loss of 805.8 million CNY and an operating loss of 175.9 million CNY, indicating a significant decline in operational efficiency and profitability.
- The company's free cash flow is negative at -879.6 million CNY, and its operating cash flow is only 14.1 million CNY, signaling potential liquidity constraints.
- The company's capital expenditures of -8.16 million CNY indicate a reduction in investment in long-term assets, which may signal a defensive strategy or financial constraints.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 600807.SS Market data — financials · 2026-05-27